Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.35 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.35 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12231840 | 1.00 | ADORA3 (0.43) | ADORA3LMNAADORA2AADORA1NPSR1 | |
| SCHEMBL1897397 | 0.88 | ADORA3 (0.45) | ADORA3LMNAADORA2AADORA1MEN1 | |
| SCHEMBL1897398 | 0.88 | ADORA3 (0.45) | ADORA3LMNAADORA2AADORA1MEN1 | |
| SCHEMBL8210284 | 0.86 | ALOX15 (0.40) | LMNANPSR1ALDH1A1NR2F2MEN1 | |
| SCHEMBL5115196 | 0.83 | MEN1 (0.43) | LMNAADORA1NPSR1ALDH1A1NR2F2 | |
| SCHEMBL5115189 | 0.83 | MEN1 (0.43) | LMNAADORA1NPSR1ALDH1A1NR2F2 | |
| SCHEMBL13406842 | 0.76 | CHUK (0.37) | FLT3TYRO3MERTKGAS6KDM4E | |
| SCHEMBL8210412 | 0.76 | CHUK (0.37) | FLT3TYRO3MERTKGAS6KDM4E | |
| SCHEMBL8202236 | 0.75 | MAPK8 (0.38) | — | |
| SCHEMBL10043016 | 0.75 | PDE4B (0.37) | FLT3TYRO3MERTKGAS6AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2012065019-A2 | PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-8044062-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha | EXELIXIS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| EP-2322523-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| CN-101715345-A | Methods of treatment using pyridopyrimidinone PI3K alpha inhibitors | EXELIXIS INC | 2010-05-26 | — | — | CN | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | PLK3, PLK4, PLK2 | ADORA3 2862/4885LMNA 303/4885ADORA2A 4437/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | ADORA3 3732/4885LMNA 736/4885ADORA2A 4011/4885 |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | PIK3CA, PIK3CD, PIK3CB | ADORA3 2221/4885LMNA 2953/4885ADORA2A 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.